Condition: Chronic Graft-versus-host-disease · Sponsor: Incyte Corporation
This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
This description comes directly from the study's public registry record.
Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
Incyte Corporation Call Center (ex-US) · +800 00027423 · eumedinfo@incyte.com
Always discuss trial participation with your own doctor first.
| University of Alabama Birmingham | Birmingham, Alabama, United States | Recruiting |
| University of Arizona Cancer Center-Out Pt. | Tucson, Arizona, United States | Recruiting |
| University of California San Diego Medical Center, Moores Cancer Center | La Jolla, California, United States | Recruiting |
| University of Southern California | Los Angeles, California, United States | Recruiting |
| UCSF | San Francisco, California, United States | Recruiting |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| Childrens National Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Miami Cancer Institute | Miami, Florida, United States | Recruiting |
| Orlando Health Cancer Institute Downtown Orlando | Orlando, Florida, United States | Recruiting |
| Memorial Cancer Institute | Pembroke Pines, Florida, United States | Recruiting |
| Emory University-Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| Northwestern Memorial Hospital | Chicago, Illinois, United States | Recruiting |
+ 113 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06585774